« Back
Home /
CHMFL-ABL-039

CHMFL-ABL-039

Item no.	HY-126143-1ea
Manufacturer	MedChem Express
CASRN	2304344-56-5
Amount	1 ea
Quantity options	100 mg 1 ea 1 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Citations	[1]Wu J, et al. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia(CML). Cancer Biol Ther. 2019;20(6):877-885.
Smiles	O=C(NC1=CN=C(NC(C2CC2)=O)C=C1)CC3=CC=C(NC(C4=CC=C(CN5CCN(C)CC5)C(C(F)(F)F)=C4)=O)C=C3
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Bcr-Abl
Shipping Temperature	Room temperature
Molecular Weight	594.63
Product Description	CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC50s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia[1].
Manufacturer - Research Area	Cancer
Solubility	10 mM in DMSO
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 ea

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question